Uncategorized
Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Email this to someone
email

PreveCeutical Announces Further Results from its Preliminary Screening of Peptides Derived from Blue Scorpion Venom in a Cell-Based Brain Cancer Model

 

 

 

 

 

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is pleased to announce further positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program  that is expected to enable the Company to generate Nature Identical™ peptide therapeutics intended for therapeutic applications. PreveCeutical’s initial focus is to understand the activities of such peptides in cell-based brain cancer models.

 

Through preliminary screening in a glioblastoma (aggressive brain cancer) cell-based assay, PreveCeutical’s research team has successfully identified four lead peptides that inhibit the activity of a target protein implicit in the progression of certain glioblastomas (see news release dated March 11, 2019).

 

After further screening of the lead peptides in an invasion assay model, PreveCeutical is pleased to announce that the peptides’ abilities to inhibit the activity of the Target Protein and the invasion potential by glioblastoma cell types has been confirmed. This is an important development given that “invasion” is a key driver of the aggressiveness, the poor prognosis and the rapid spread of glioblastoma.

 

Although this screening process is nearing completion, the Peptide Program is ongoing. This latest encouraging development has helped progress the Company towards assessing the efficacy of the lead peptides in more sophisticated neural oncosphere cell models of glioblastoma. The results from such additional screening will be helpful in determining further applications of research generated from the Peptide Program.

 

About PreveCeutical

 

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

 

PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the soluble gel drug delivery program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

 

Posted April 10, 2019

Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Email this to someone
email

MORE or "UNCATEGORIZED"


Vapen MJ Ventures Closes CDN$6.1 Million Oversubscribed Non-Brokered Private Placement

Vapen MJ Ventures Corporation (CSE: VAPN) is pleased to announce ... READ MORE

May 23, 2019

AcuityAds Announces Closing of CDN$9.2 Million Bought Deal Offering

AcuityAds Holdings Inc. (TSX-V:AT), a technology leader that prov... READ MORE

May 23, 2019

EpiBone, Inc. Receives FDA Clearance to Commence its First-In-Human, Phase 1/2 Trial of its Bone Product, EB-CMF

EpiBone, Inc. today announced that the U.S. Food and Drug Adminis... READ MORE

May 23, 2019

Ultrasound Scanners Market to Skyrocket with AI, Cloud, and Portable and Ultra-portable Systems

The mature, yet dynamic ultrasound market generated $6.12 billion... READ MORE

May 23, 2019

Canopy Growth acquires established skincare and well-being company This Works®

Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) has finalized a... READ MORE

May 23, 2019

Copyright 2019 The Venture Report